AAN 2024: Novel Approaches to Parkinson Disease Care

Daniel Kremens, MD, JD, provided commentary on a number of various amantadine formulations for Parkinson disease, and how timing of dosing impacts efficacy.

In this conversation, Kremens discussed the common use of antiemetics in Parkinson disease, the real-world data surrounding these agents, and whether there are certain clinical advantages to apomorphine hydrochloride injection.

Kremens gave thoughts on the use of several investigational continuous agents, including IPX203, risvodetinib, and P2B001.

In this segment, Kremens described pump therapies currently in development, such as ND0612 and ABBV-951.

Daniel Kremens, MD, JD, described positive 18-month data on bemdaneprocel, an investigational cell-based approach for patients with Parkinson disease.

Kremens gave closing thoughts on the promise of the Parkinson disease research field, the outlook of drug development, and what clinicians should be excited for next.